Publications by authors named "D Ternant"
Article Synopsis
- Mycophenolate mofetil (MMF) is used to treat interstitial lung disease (ILD), but its pharmacokinetics in this context weren't previously known. This study aimed to describe the variability of MPA pharmacokinetics in ILD patients using population modeling.
- MPA levels were measured in 27 ILD patients over an 8-hour period after administering 1000 mg MMF twice daily, and the best fit for its pharmacokinetics was a two-compartment model influenced by factors like body weight and renal function.
- This research represents the first exploration of MPA pharmacokinetics in ILD and suggests that MPA behaves similarly to other applications, warranting further investigation.
Article Synopsis
- Eculizumab is a medicine used to treat certain kidney diseases, and scientists want to find a better way to give the right amount to patients, avoiding high doses that can be costly.
- They studied blood samples from 44 patients to understand how the drug leaves the body and whether a new model can predict its levels better than a simple one.
- The results showed that how eculizumab is eliminated from the body isn’t straightforward and depends on the person’s weight, which helps doctors decide the best dose for each patient.
Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases.
Pediatr Rheumatol Online J
January 2024
Article Synopsis
- The study examines the pharmacokinetics (PK) of adalimumab in pediatric rheumatic diseases (PRD) and how methotrexate treatment affects its levels, as prior data on this topic is limited.
- Conducted over 12 weeks with 28 patients, the research compared adalimumab concentrations in two groups: those receiving adalimumab with methotrexate and those receiving adalimumab alone.
- Results showed variability in adalimumab levels across patients, with those on methotrexate exhibiting slightly higher overall exposure, but the difference in median concentrations was not statistically significant.
Aims: The exposure-response relationship of bevacizumab may be confounded by various factors, including baseline characteristics, time-dependent target engagement and recursive relationships between exposure and response, requiring effective mitigation. This study aimed to investigate the exposure-response relationships of bevacizumab in metastatic colorectal cancer (mCRC) patients while mitigating potential biases.
Methods: Bevacizumab pharmacokinetics was described using target-mediated drug disposition modelling.
Childhood immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by isolated thrombocytopenia. Prolonged ITP (persistent and chronic) leads to a reduced quality of life for children in many domains. To provide optimal support for children, with ITP, it is important to be able to predict those who will develop prolonged ITP.
View Article and Find Full Text PDF